Print this page    •   Back to Web version of article

News Flash!! Once-a-Day Triple NRTI Warning

October 27, 2003

Gilead Sciences, Inc., the manufacturer of the anti-HIV medication Tenofovir (Viread) today issued a "Dear Health Care Professional" letter (click here to view) describing high rates of virologic failure in patients treated with a "once-a-day" triple NRTI regimen that contains: Didanosine (ddI, Videx EC), Lamivudine (3TC, Epivir), and Tenofovir (Viread). This letter is somewhat technical and difficult to understand. Please call Roberto González at 206-957-1659 or 1-888-399-7837 if you would like further explanation.


Back to the STEP Ezine Volume 1, Issue 51 contents page.




This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art2058.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.